MedTrace Logo

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

NCT04414163 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-04-24

No results posted yet for this study

Summary

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

Conditions

  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Extranodal NK/T-cell Lymphoma

Interventions

DRUG

IMC-001

Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)

Sponsors & Collaborators

  • ImmuneOncia Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Won Seog Kim · Samsung Medical Center, Republic of Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2024-07-23
Completion
2027-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414163 on ClinicalTrials.gov